Kairos Pharma's ENV-105 Shows Significant Survival Benefit in Prostate Cancer Trial

Kairos Pharma's ENV-105 doubled median progression-free survival in metastatic castration-resistant prostate cancer patients, potentially offering a new way to overcome treatment resistance.

Chicago Metrowire Staff
••Healthcare
Kairos Pharma's ENV-105 Shows Significant Survival Benefit in Prostate Cancer Trial

Kairos Pharma Ltd. (NYSE American: KAPA) presented interim efficacy results for its lead candidate ENV-105 at the 11th International Conference on Cancer Research & Drug Development in Houston on Nov. 3, 2026. The data, disclosed by President and Chief Scientific Officer Neil Bhowmick, showed a statistically significant improvement in median progression-free survival (PFS) for patients with metastatic castration-resistant prostate cancer (mCRPC) when ENV-105 was added to apalutamide. Median PFS was 17.7 months for the combination versus two months for apalutamide alone (P=0.0008).

The magnitude of the benefit matters because mCRPC is an aggressive, late-stage disease where patients typically progress quickly on existing therapies. A PFS improvement of more than 15 months suggests ENV-105 may meaningfully delay disease progression, a key goal in oncology. The company said the trial will now focus on first-line therapy after enzalutamide, incorporating first-line resistance in a larger patient group, which could position ENV-105 earlier in the treatment sequence.

ENV-105 is a first-in-class antibody targeting CD105, a protein the company identifies as a key driver of resistance and relapse to standard therapies. The drug is also being evaluated in a Phase 1 trial for EGFR-driven non-small cell lung cancer. Previous preclinical research demonstrated the potential of ENV-105 to enhance radiation sensitivity in prostate cancer models, suggesting broader applications beyond prostate cancer. Bhowmick said the findings support the hypothesis that targeting CD105 may interrupt mechanisms of treatment resistance and restore sensitivity to established cancer therapies.

For investors, the interim Phase 2 results provide a clinical validation milestone for Kairos Pharma, a clinical-stage biopharmaceutical company based in Los Angeles. The full press release is available at https://ibn.fm/PIrky, and ongoing updates can be found in the company’s newsroom at https://ibn.fm/KAPA. The announcement was disseminated through TinyGems, a communications platform focused on small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio within IBN, which provides wire distribution through InvestorWire and other corporate communications solutions.

The interim data also carry implications for the broader field of drug resistance research. If CD105 inhibition can restore sensitivity to apalutamide and potentially other therapies, it could open a new treatment paradigm for cancers that have become refractory to standard care. However, the results are interim and based on a limited patient population; the company’s decision to expand the trial to first-line post-enzalutamide patients indicates a strategic shift to generate more robust evidence. As with all clinical-stage biotech investments, risks remain, including the need for larger trials and regulatory review. Terms of use and disclaimers for the TinyGems content are available at https://www.TinyGems.com/Disclaimer.

Blockchain Registration

QR Code for Blockchain Registration